Medicare billing address
CMS Medicare provider billing file
30 Lawrence RdSuite 201
Broomall, PA 19008
CMS public data · NPI 1609899418
CMS public files list billing, prescribing, location, and participation fields for this NPI. Current plan networks, appointment availability, clinical outcomes, and patient-specific medical advice require separate verification.
CMS display name
Nabila Chowdhury, M.D.
Specialty
Credential
M.D.
NPI
1609899418
Primary source state
PA
Data retrieval date
July 28, 2026
Where these numbers come from, and what they cannot tell you
Public CMS records, 2024 reporting year. These are historical Medicare fields, not proof of current coverage, appointment availability, quality, or what someone will pay.
This page shows Medicare billing and Part D prescribing data for Nabila Chowdhury, M.D. from CMS public files. It covers 2024 claims data: services billed, the beneficiary panel, and the most-prescribed Part D drugs. It does not show current coverage, appointment availability, or quality ratings.
A licensed agent, not a call center
Peter Abilla, Licensed Medicare Insurance Sales Agent, NPN 22265186. Bring the doctors and prescriptions that matter to you, then check the details before you enroll.
Medicare participating
Yes
Individual assignment
Yes
Group assignment
Yes
CMS opt-out records
0
When CMS files list more than one address for the same NPI, each address stays tied to the CMS file that reported it.
CMS Medicare provider billing file
30 Lawrence RdCMS Doctors & Clinicians file
30 Lawrence RdIn the 2024 CMS provider billing file, this NPI had 283 Medicare beneficiaries and 35,654 total services. The average beneficiary age was 75, and the average HCC risk score was 1.5.
Total Medicare allowed amount
$598,348.48
Total Medicare payment amount
$470,669.40
Medicare beneficiaries
283
Total services
35,654
These percentages describe the Medicare beneficiary panel in the CMS utilization file. They are not a diagnosis for any individual patient and are not a quality score.
Hyperlipidemia
75%
CMS beneficiary-panel share
Hypertension
73%
CMS beneficiary-panel share
Osteoporosis
37%
CMS beneficiary-panel share
Diabetes
27%
CMS beneficiary-panel share
Ischemic heart disease
27%
CMS beneficiary-panel share
Anxiety
27%
CMS beneficiary-panel share
Where these service numbers come from, and what they cannot tell you
Amounts shown are average Medicare-approved amounts per billed unit in CMS records. What a person pays depends on current coverage and cannot be read from this table alone.
| CMS service description | Services | Avg allowed |
|---|---|---|
| Injection, denosumab, 1 mg | 2,340 | $25.42 |
| Injection, dexamethasone sodium phosphate, 1 mg | 1,575 | $0.11 |
| Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more | 551 | $185.11 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 544 | $7.61 |
| Insertion of needle into vein for collection of blood sample | 445 | $8.65 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 194 | $36.48 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 125 | $29.13 |
| Unclassified drugs | 101 | $0.83 |
| Administration of chemotherapy into vein, 1 hour or less | 95 | $133.67 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 67 | $119.93 |
Where these Part D numbers come from, and what they cannot tell you
CMS data reports historical prescription drug events attributed to NPI 1609899418. Formularies, copays, prior authorization, and step therapy rules vary by current coverage.
| Rank | Drug | Generic name | Total claims | 30-day fills | Total drug cost |
|---|---|---|---|---|---|
| 1 | Anastrozole | Anastrozole | 358 | 954 | $8,696.33 |
| 2 | Ibrance | Palbociclib | 48 | 48 | $743,938.10 |
| 3 | Letrozole | Letrozole | 38 | 94 | $886.73 |
| 4 | Fulvestrant | Fulvestrant | 35 | 35 | $15,836.51 |
| 5 | Xgeva | Denosumab | 32 | 32 | $98,026.86 |
| 6 | Famotidine | Famotidine | 29 | 57 | $316.48 |
| 7 | Tamoxifen Citrate | Tamoxifen Citrate | 25 | 59.3 | $649.21 |
| 8 | Exemestane | Exemestane | 18 | 48 | $2,690.83 |
| 9 | Eliquis | Apixaban | 17 | 35 | $20,611.05 |
| 10 | Ondansetron Hcl | Ondansetron Hcl | 15 | 15 | $180.32 |
CMS Part D records are historical aggregate claims data. They do not include current formulary status, pharmacy price, prior-authorization rules, network-directory status, or clinical-outcome data.
Graduation year
1999
Group/practice field
Consultants In Medical Oncology And Hematology Pc
Telehealth reported
Not reported
Verify plan-directory status, drug formulary rules, pharmacy pricing, appointment availability, and clinical questions against current plan documents and the relevant provider or care team.
The numbers above come from CMS public-use files for this NPI. Each link identifies the CMS release used and the retrieval date.